WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Friday, December 14, 2007

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT; PLUR=YES; OP=ADJ	
☐	L7	L6 and (@AD<20030630 or @PRAD<20030630 or @RLAD<20030630)	19
☐	L6	L4 and ((fatty or palmitic or eicosanoic or capric or lauric or myristic or palmitic or stearic or arachic oleic) same amide)	23
☐	L5	L4 and (fatty or palmitic or eicosanoic or capric or lauric or myristic or palmitic or stearic or arachic oleic)	150
☐	L4	L3 and glycoprotein	324
☐	L3	L1 and (sial$ or disial$)	519
☐	L2	L1 and (asparagine same (sial$ or disial$) same (fatty or palmitic or eicosanoic or capric or lauric or myristic or palmitic or stearic or arachic oleic))	2
☐	L1	514/42.icls. or 514/42.ccls. or 514/54.icls. or 514/54.ccls. or 536/29.1.icls. or 536/29.1.ccls.	4441

END OF SEARCH HISTORY

```
     FILE 'HCAPLUS' ENTERED AT 16:11:32 ON 14 DEC 2007
L1        47700 S SIAL? OR DISIAL?
L2        62755 S ASPARAGINE OR ASP
L3       348157 S (FATTY ACID) OR HEXANOIC OR HEPTANOIC OR OCTANOIC OR NONANOIC
L4        25132 S INFLUENZA
L5         1016 S L1 AND L2
L6           29 S L1 AND L2 AND L3
L7           36 S L1 AND L2 AND L4
L8            7 S L1 AND L2 AND L3 AND L4
L9          907 S L5 AND (PY<2004 OR AY<2004 OR PRY<2004)
L10          16 S L6 AND (PY<2004 OR AY<2004 OR PRY<2004)
L11          27 S L7 AND (PY<2004 OR AY<2004 OR PRY<2004)
L12           5 S L8 AND (PY<2004 OR AY<2004 OR PRY<2004)

     FILE 'REGISTRY' ENTERED AT 16:42:38 ON 14 DEC 2007
L13             STRUCTURE UPLOADED
L14           2 S L13
L15          38 S L13 SSS FULL
L16             STRUCTURE UPLOADED
L17          50 S L16
L18           5 S L16  SUB=L15 FULL

     FILE 'CAPLUS' ENTERED AT 16:44:36 ON 14 DEC 2007
L19           2 S L18
L20           2 S L15/THU
```

```
=> file hcaplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         1.26       1.26

FILE 'HCAPLUS' ENTERED AT 16:11:32 ON 14 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 14 Dec 2007  VOL 147 ISS 26
FILE LAST UPDATED: 13 Dec 2007  (20071213/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s sial? or disial?

         47218 SIAL?
          1149 DISIAL?
L1        47700 SIAL? OR DISIAL?

=> s asparagine or asp

         32992 ASPARAGINE
         31302 ASP
L2        62755 ASPARAGINE OR ASP

=> s (fatty acid) or hexanoic or heptanoic or octanoic or nonanoic or decanoic or
eixosino? or capric or lauric or myristic or palmitic or stearic or arachic or
behenic or oleic

        393480 FATTY
       4497911 ACID
        219923 FATTY ACID
                  (FATTY(W)ACID)
         15521 HEXANOIC
          6189 HEPTANOIC
         13044 OCTANOIC
          5014 NONANOIC
          9165 DECANOIC
             0 EIXOSINO?
          5955 CAPRIC
         19472 LAURIC
         15669 MYRISTIC
         41059 PALMITIC
         73454 STEARIC
           521 ARACHIC
          4931 BEHENIC
         68307 OLEIC
L3      348157 (FATTY ACID) OR HEXANOIC OR HEPTANOIC OR OCTANOIC OR NONANOIC
```

```
                OR DECANOIC OR EIXOSINO? OR CAPRIC OR LAURIC OR MYRISTIC OR PALM
                ITIC OR STEARIC OR ARACHIC OR BEHENIC OR OLEIC

=> s influenza

L4        25132 INFLUENZA

=> s l1 and l2

L5         1016 L1 AND L2

=> s l1 and l2 and l3

L6           29 L1 AND L2 AND L3

=> s l1 and l2 and l4

L7           36 L1 AND L2 AND L4

=> s l1 and l2 and l3 and l4

L8            7 L1 AND L2 AND L3 AND L4

=> s l5 and (PY<2004 or AY<2004 or PRY<2004)

       23975080 PY<2004
        4753779 AY<2004
        4236023 PRY<2004
L9           907 L5 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s l6 and (PY<2004 or AY<2004 or PRY<2004)

       23975080 PY<2004
        4753779 AY<2004
        4236023 PRY<2004
L10           16 L6 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s l7 and (PY<2004 or AY<2004 or PRY<2004)

       23975080 PY<2004
        4753779 AY<2004
        4236023 PRY<2004
L11           27 L7 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s l8 and (PY<2004 or AY<2004 or PRY<2004)

       23975080 PY<2004
        4753779 AY<2004
        4236023 PRY<2004
L12            5 L8 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> file stnguide

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 2.60       3.86

FILE 'STNGUIDE' ENTERED AT 16:11:55 ON 14 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Dec  7, 2007 (20071207/UP).
```

```
=> d l12 1-5 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y


L12  ANSWER 1 OF 5  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Soluble derivatives of human neutral hyaluronidase and preparation with
     transgenic cells for use in therapeutic modulation of glycosaminoglycan
     metabolism
AB   The invention relates to the discovery of novel soluble neutral active
     Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use
     to facilitate administration of other mols. or to alleviate
     glycosaminoglycan associated pathologies.  Minimally active polypeptide
     domains of the soluble, neutral active sHASEGP domains are described that
     include asparagine-linked sugar moieties required for a
     functional neutral active hyaluronidase domain.  Included are modified
     amino-terminal leader peptides that enhance secretion of sHASEGP.  The
     invention further comprises sialated and pegylated forms of a
     recombinant sHASEGP to enhance stability and serum pharmacokinetics over
     naturally occurring slaughterhouse enzymes.  Further described are
     suitable formulations of a substantially purified recombinant sHASEGP
     glycoprotein derived from a eukaryotic cell that generate the proper
     glycosylation required for its optimal activity.
AN   2005:1242684  HCAPLUS <<LOGINID::20071214>>
DN   143:474231
TI   Soluble derivatives of human neutral hyaluronidase and preparation with
     transgenic cells for use in therapeutic modulation of glycosaminoglycan
     metabolism
IN   Bookbinder, Louis H.; Kundu, Anirban; Frost, Gregory I.; Haller, Michael
     F.; Keller, Gilbert A.; Dylan, Tyler M.
PA   Halozyme, Inc., USA
SO   U.S. Pat. Appl.-Publ., 121 pp., Cont.-in-part of U.S. Ser. No. 795,095.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 3
     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
PI   US 2005260186         A1    20051124    US 2005-65716            20050223 <--
     US 2004268425         A1    20041230    US 2004-795095           20040305 <--
     US 2006104968         A1    20060518    US 2005-238171           20050927 <--
     AU 2006216545         A1    20060831    AU 2006-216545           20060223
     CA 2598823            A1    20060831    CA 2006-2598823          20060223
     WO 2006091871         A1    20060831    WO 2006-US6700           20060223
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
             KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
             MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
             SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
             VN, YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
     EP 1858926            A1    20071128    EP 2006-736105           20060223
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
     IN 2007DN07053        A     20071005    IN 2007-DN7053           20070912
PRAI US 2003-452360P       P     20030305  <--
     US 2004-795095        A2    20040305
     US 2005-65716         A2    20050223
     US 2005-238171        A     20050927
```

WO 2006-US6700 W 20060223

L12 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Differentially expressed gene profile for diagnosing and treating mental disorders
AB The present invention provides methods for diagnosing mental disorders (e.g., psychotic disorders such as schizophrenia). The present invention uses DNA microarray anal. to demonstrate differential expression of genes in selected regions of post-mortem brains from patients diagnosed with mental disorders in comparison with normal control subjects. The invention also provides methods of identifying modulators of such mental disorders as well as methods of using these modulators to treat patients suffering from such mental disorders.
AN 2005:447673 HCAPLUS <<LOGINID::20071214>>
DN 143:20875
TI Differentially expressed gene profile for diagnosing and treating mental disorders
IN Akil, Huda; Atz, Mary; Bunney, William E., Jr.; Choudary, Prabhakara V.; Evans, Simon J.; Jones, Edward G.; Li, Jun; Lopez, Juan F.; Myers, Richard; Thompson, Robert C.; Tomita, Hiroaki; Vawter, Marquis P.; Watson, Stanley
PA The Board of Trustees of the Leland Stanford Junior University, USA
SO PCT Int. Appl., 226 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005046434	A2	20050526	WO 2004-US36784	20041105 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005209181	A1	20050922	US 2004-982556	20041104 <--
AU 2004289247	A1	20050526	AU 2004-289247	20041105 <--
CA 2543811	A1	20050526	CA 2004-2543811	20041105 <--
EP 1680009	A2	20060719	EP 2004-800741	20041105 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
PRAI US 2003-517751P	P	20031105 <--		
US 2004-982556	A	20041104		
WO 2004-US36784	W	20041105		

L12 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug containing the same
AB Disclosed are a disialoundecasaccharide chain asparagine /fatty acid amide, a medical drug containing the same, and a medical drug containing disialoundecasaccharide chain asparagine. A disialoundecasaccharide chain asparagine-decanoic acid amide was prepared from actinase-E-treated sialylglycopeptide (SGP) and decanoic acid. The obtained compound showed anti-influenzavirus activity in vitro.
AN 2005:14446 HCAPLUS <<LOGINID::20071214>>
DN 142:120505

TI Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug containing the same
IN Kajihara, Yasuhiro; Maeda, Hiroaki; Fukae, Kazuhiro
PA Otsuka Chemical Co., Ltd., Japan; Sanyo Chemical Industries, Ltd.
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005000906	A1	20050106	WO 2004-JP9521	20040629 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004252028	A1	20050106	AU 2004-252028	20040629 <--
	CA 2529162	A1	20050106	CA 2004-2529162	20040629 <--
	EP 1640383	A1	20060329	EP 2004-746990	20040629 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1809594	A	20060726	CN 2004-80017447	20040629 <--
	US 2007105813	A1	20070510	US 2005-562059	20051222 <--
PRAI	JP 2003-187931	A	20030630 <--		
	WO 2004-JP9521	W	20040629		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Novel pharmaceutical composition of interferon gamma or pirfenidone combined with molecular diagnostics for the improved treatment of interstitial lung diseases
AB The present invention relates to a novel pharmaceutical composition of compds. having the biol. activity of interferon gamma (IFN-γ) or pirfenidone in combination with a diagnostic array of candidate polynucleotides for the improved treatment of all forms of interstitial lung diseases, in particular of idiopathic pulmonary fibrosis (IPF). This invention describes the combination of mol. diagnosis and clin. therapy as a novel medication principle for reduction of mortality and improvement of disease management in interstitial lung diseases.
AN 2003:491063 HCAPLUS <<LOGINID::20071214>>
DN 139:57897
TI Novel pharmaceutical composition of interferon gamma or pirfenidone combined with molecular diagnostics for the improved treatment of interstitial lung diseases
IN Bevec, Dorian; Ziesche, Rolf
PA Mondobiotech SA, Switz.
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003051388	A2	20030626	WO 2002-CH691	20021212 <--
	WO 2003051388	A3	20031030		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

```
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
            RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
            VN, YU, ZA, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
            CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2470763          A1    20030626    CA 2002-2470763        20021212 <--
    AU 2002347182       A1    20030630    AU 2002-347182         20021212 <--
    BR 2002007310       A     20040817    BR 2002-7310           20021212 <--
    EP 1455813          A2    20040915    EP 2002-782602         20021212 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
    CN 1620309          A     20050525    CN 2002-828206         20021212 <--
    JP 2005528082       T     20050922    JP 2003-552321         20021212 <--
    NO 2003003642       A     20031017    NO 2003-3642           20030815 <--
    US 2006270618       A1    20061130    US 2004-498079         20040608 <--
    IN 2004DN07852      A     20070427    IN 2004-DN7852         20040615 <--
    IN 2004DN01679      A     20070525    IN 2004-DN1679         20040615 <--
PRAI EP 2001-130011     A     20011218  <--
    WO 2002-CH691       W     20021212  <--

L12  ANSWER 5 OF 5  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Endocrine disruptor screening using DNA chips of endocrine
     disruptor-responsive genes
AB   A method and kit for detecting endocrine-disrupting chems. using DNA
     microarrays are claimed.  The method comprises preparing a nucleic acid
     sample containing mRNAs or cDNAs originating in cells, tissues, or organisms
     which have been brought into contact with a sample containing the endocrine
     disruptor.  The nucleic acid sample is hybridized with DNA microarrays
     having genes affected by the endocrine disruptor or DNA fragments
     originating in these genes have been fixed.  The results obtained are then
     compared with the results obtained with the control sample to select the
     gene affected by the endocrine disruptor.  Genes whose expression is
     altered by tri-Bu tin, 4-octaphenol, 4-nonylphenol, di-N-Bu phthalate,
     dichlorohexyl phthalate, octachlorostyrene, benzophenone, diethylhexyl
     phthalate, diethylstilbestrol (DES), and 17-β estradiol (E2), were
     found in mice by DNA chip anal..
AN   2002:937303  HCAPLUS <<LOGINID::20071214>>
DN   138:20443
TI   Endocrine disruptor screening using DNA chips of endocrine
     disruptor-responsive genes
IN   Kondo, Akihiro; Takeda, Takeshi; Mizutani, Shigetoshi; Tsujimoto,
     Yoshimasa; Takashima, Ryokichi; Enoki, Yuki; Kato, Ikunoshin
PA   Takara Bio Inc., Japan
SO   Jpn. Kokai Tokkyo Koho, 386 pp.
     CODEN: JKXXAF
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   JP 2002355079       A      20021210    JP 2002-69354          20020313 <--
PRAI JP 2001-73183       A      20010314  <--
     JP 2001-74993       A      20010315  <--
     JP 2001-102519      A      20010330  <--


=> d his

     (FILE 'HOME' ENTERED AT 16:08:17 ON 14 DEC 2007)
```

```
     FILE 'HCAPLUS' ENTERED AT 16:11:32 ON 14 DEC 2007
L1         47700 S SIAL? OR DISIAL?
L2         62755 S ASPARAGINE OR ASP
L3        348157 S (FATTY ACID) OR HEXANOIC OR HEPTANOIC OR OCTANOIC OR NONANOIC
L4         25132 S INFLUENZA
L5          1016 S L1 AND L2
L6            29 S L1 AND L2 AND L3
L7            36 S L1 AND L2 AND L4
L8             7 S L1 AND L2 AND L3 AND L4
L9           907 S L5 AND (PY<2004 OR AY<2004 OR PRY<2004)
L10           16 S L6 AND (PY<2004 OR AY<2004 OR PRY<2004)
L11           27 S L7 AND (PY<2004 OR AY<2004 OR PRY<2004)
L12            5 S L8 AND (PY<2004 OR AY<2004 OR PRY<2004)

     FILE 'STNGUIDE' ENTERED AT 16:11:55 ON 14 DEC 2007

     FILE 'HCAPLUS' ENTERED AT 16:12:23 ON 14 DEC 2007

     FILE 'STNGUIDE' ENTERED AT 16:12:23 ON 14 DEC 2007

=> log hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.06      20.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -3.90

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:12:30 ON 14 DEC 2007

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'STNGUIDE' AT 16:15:51 ON 14 DEC 2007
FILE 'STNGUIDE' ENTERED AT 16:15:51 ON 14 DEC 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.06      20.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -3.90

=> d l11 1-27 ti
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y



L11  ANSWER 1 OF 27  HCAPLUS  COPYRIGHT 2007 ACS on STN
TI   Soluble hyaluronidases and methods of their preparation and therapeutic
     uses in glycosaminoglycan-associated disorders
```

L11 ANSWER 2 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Soluble derivatives of human neutral hyaluronidase and preparation with transgenic cells for use in therapeutic modulation of glycosaminoglycan metabolism

L11 ANSWER 3 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI GM1 binding deficient exotoxins for use as immunoadjuvants

L11 ANSWER 4 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Differentially expressed gene profile for diagnosing and treating mental disorders

L11 ANSWER 5 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug containing the same

L11 ANSWER 6 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Glycotentacles: synthesis of cyclic glycopeptides, toward a tailored blocker of influenza virus hemagglutinin

L11 ANSWER 7 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Virus capture material and virus sensor

L11 ANSWER 8 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Chitosans modified with glycoprotein sugar chains and their preparation

L11 ANSWER 9 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Porcine Pulmonary Collectins Show Distinct Interactions with Influenza A Viruses: Role of the N-Linked Oligosaccharides in the Carbohydrate Recognition Domain

L11 ANSWER 10 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Novel pharmaceutical composition of interferon gamma or pirfenidone combined with molecular diagnostics for the improved treatment of interstitial lung diseases

L11 ANSWER 11 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Change in receptor binding ability of human influenza A viruses

L11 ANSWER 12 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Endocrine disruptor screening using DNA chips of endocrine disruptor-responsive genes

L11 ANSWER 13 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Color and shape changing polymeric ribbons and sheets

L11 ANSWER 14 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Porcine surfactant protein D is N-glycosylated in its carbohydrate recognition domain and is assembled into differently charged oligomers

L11 ANSWER 15 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Amino acids responsible for the absolute sialidase activity of the influenza A virus neuraminidase: relationship to growth in the duck intestine

L11 ANSWER 16 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Change in Receptor-Binding Specificity of Recent Human Influenza A Viruses (H3N2): A Single Amino Acid Change in Hemagglutinin Altered Its Recognition of Sialyloligosaccharides

L11 ANSWER 17 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Synthesis of bioactive cycloglycopeptides.

L11 ANSWER 18 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en

L11 ANSWER 19 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI The glycosylation of the influenza A virus hemagglutinin by mammalian cells. A site-specific study

L11 ANSWER 20 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Chemical and enzymic synthesis of multivalent sialoglycopeptides

L11 ANSWER 21 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Pocket Mutations of HLA-B27 Show That Anchor Residues Act Cumulatively to Stabilize Peptide Binding

L11 ANSWER 22 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Design and Synthesis of a Biologically Active Antibody Mimic Based on an Antibody-Antigen Crystal Structure

L11 ANSWER 23 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Crystal structure of a bacterial sialidase (from Salmonella typhimurium LT2) shows the same fold as an influenza virus neuraminidase

L11 ANSWER 24 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor

L11 ANSWER 25 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 Å resolution

L11 ANSWER 26 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Conserved sequences in bacterial and viral sialidases

L11 ANSWER 27 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Variant influenza virus hemagglutinin that induces fusion at elevated pH

=> d l11 5 6 11 17 20 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L11 ANSWER 5 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug containing the same
AB Disclosed are a disialoundecasaccharide chain asparagine /fatty acid amide, a medical drug containing the same, and a medical drug containing disialoundecasaccharide chain asparagine. A disialoundecasaccharide chain asparagine-decanoic acid amide was prepared from actinase-E-treated sialylglycopeptide (SGP) and decanoic acid. The obtained compound showed anti-influenzavirus activity in vitro.
AN 2005:14446 HCAPLUS <<LOGINID::20071214>>
DN 142:120505
TI Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug containing the same
IN Kajihara, Yasuhiro; Maeda, Hiroaki; Fukae, Kazuhiro
PA Otsuka Chemical Co., Ltd., Japan; Sanyo Chemical Industries, Ltd.
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005000906	A1	20050106	WO 2004-JP9521	20040629 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004252028	A1	20050106	AU 2004-252028	20040629 <--
	CA 2529162	A1	20050106	CA 2004-2529162	20040629 <--
	EP 1640383	A1	20060329	EP 2004-746990	20040629 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1809594	A	20060726	CN 2004-80017447	20040629 <--
	US 2007105813	A1	20070510	US 2005-562059	20051222 <--
PRAI	JP 2003-187931	A	20030630 <--		
	WO 2004-JP9521	W	20040629		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Glycotentacles: synthesis of cyclic glycopeptides, toward a tailored blocker of influenza virus hemagglutinin
AB A cyclic peptide, cyclo(Ser-Gly-Gly-Gln-Ser-His-Asp)3, is an excellent scaffold for the synthesis of a cyclic glycopeptide carrying GM3 oligosaccharides with a potent inhibitory effect on the hemagglutination induced by the influenza virus. Tridentate binding of the glycopeptide is shown to produce a much greater inhibitory effect than di- or monodentate binding. The shape of the glycopeptide protein scaffold, which is determined by the amino acid sequence employed, is also found to be significant in determining the inhibitory activity.
AN 2003:909487 HCAPLUS <<LOGINID::20071214>>
DN 140:94283
TI Glycotentacles: synthesis of cyclic glycopeptides, toward a tailored blocker of influenza virus hemagglutinin
AU Ohta, Takashi; Miura, Nobuaki; Funitani, Naoki; Nakajima, Fumio; Niikura, Kenichi; Sadamoto, Reiko; Guo, Chao-Tan; Suzuki, Takashi; Suzuki, Yasuo; Monde, Kenji; Nishimura, Shin-Ichiro
CS Division of Biology Sciences, Graduate School of Science, Hokkaido University, Sapporo, 001-0021, Japan
SO Angewandte Chemie, International Edition (2003), 42(42), 5186-5189
CODEN: ACIEF5; ISSN: 1433-7851
PB Wiley-VCH Verlag GmbH & Co. KGaA
DT Journal
LA English
OS CASREACT 140:94283
RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Change in receptor binding ability of human influenza A viruses
AB A review on the author's studies on the changes in hemagglutinin (HA) of human influenza A viruses and its recognition of sialyloligosaccharides. Human H3N2 influenza A viruses isolated after 1992 agglutinated human red blood cells (RBC) but not chicken RBC (CRBC). An amino acid change from Glu to Asp at

position 190 of HA of these viruses was responsible for the loss of the ability to bind to CRBC. These viruses did not agglutinate CRBC treated with 2,3-sialidase, but they agglutinated derivatized CRBC resialylated with 2,6-sialic acid. Effects of the alteration of the receptor-binding ability on virus proliferation and affinity of these viruses with influenza receptors were also studied.

AN 2003:469255 HCAPLUS <<LOGINID::20071214>>
DN 139:81709
TI Change in receptor binding ability of human influenza A viruses
AU Nobusawa, Eri
CS Dep. Virol., Nagoya City Univ. Med. Sch., Nagoya, Japan
SO Nagoya-shiritsu Daigaku Igakkai Zasshi (2003), 54(1), 23-28
CODEN: NASDA6; ISSN: 0027-7606
PB Nagoya-shiritsu Daigaku Igakkai
DT Journal; General Review
LA Japanese

L11 ANSWER 17 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Synthesis of bioactive cycloglycopeptides.
AB Cycloglycopeptide as specific inhibitor of influenza virus infection was prepared by combined use of chemical and enzymic strategy. Hemagglutinin consisting of hetero trimers is exposed on the surface of influenza virus. The mol. recognition between hemaggltinin and sialic acids of the host-cell surface leads the cell-virus adhesion stage. As novel type of inhibitor of influenza virus infection, we designed cycloglycopeptide carrying sialic acids pendants. Here, each pendant was placed with appropriate distance from each other. Firstly, an aspartic acid residue was introduced onto 2-chlorotrityl resin using β-carboxyl group and liner [Ser-Gly-Gly-Gln-Ser-His-Asp]3 was synthesized according to Fmoc/DCC/HOBt method based on solid phase peptide synthesizer. After deprotection of C-terminal, this liner peptide was converted into cyclic peptide by intra-cyclization reaction. Next, lactose derivative having alkylamino group at reducing end was transferred the glutamine residues of the cyclopepride using transglutaminase-catalized reaction. Further sugar elongation reaction with sialic acid was subsequently achieved by employing sialyltransferase to yield the target compound Structural evaluation and biol. activity of this compound will be discussed.

AN 2000:327724 HCAPLUS <<LOGINID::20071214>>
TI Synthesis of bioactive cycloglycopeptides.
AU Ota, Takashi; Nishimura, Shin-Ichiro
CS Laboratory for Bio-Macromolecular Chemistry, Division of Biological Sciences, Graduate School of Science, Hokkaido University, Sappro, Japan
SO Book of Abstracts, 219th ACS National Meeting, San Francisco, CA, March 26-30, 2000 (2000), CARB-047 Publisher: American Chemical Society, Washington, D. C.
CODEN: 69CLAC
DT Conference; Meeting Abstract
LA English

L11 ANSWER 20 OF 27 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Chemical and enzymic synthesis of multivalent sialoglycopeptides
AB Linear and branched glycopeptides containing multiple sialyl -N-acetyllactosamine side chains have been synthesized using a combined chemical and enzymic approach. Peptide backbones in which β-GlcNAc-Asn residues were incorporated were obtained in good yields by optimized solid-phase synthesis following the Boc strategy. The resulting multivalent glycopeptides were galactosylated in near-quant. yields using bovine galactosyltransferase, UDP-galactose, and calf alkaline phosphatase that destroys the inhibiting side product UDP. Subsequent enzymic sialylation yielded the desired glycopeptides containing asparagine-linked sialyl-N-acetyllactosamine side chains. The compds. were characterized by 1H NMR and FABMS. Recombinant sialyltransferase and CMP-sialate synthetase were used

for the enzymic synthesis of sialosides on a preparative scale. The synthetic glycopeptides were tested as inhibitors of influenza virus to cells, revealing that most of the multivalent sialoglycopeptides exhibit increased binding that depends on the spacing when compared to monovalent compds. A possible mechanism for increased binding is proposed.
AN 1994:509622 HCAPLUS <<LOGINID::20071214>>
DN 121:109622
TI Chemical and enzymic synthesis of multivalent sialoglycopeptides
AU Unverzagt, Carlo; Kelm, Soerge; Paulson, James C.
CS Sch. Med., UCLA, Los Angeles, CA, 90024-1737, USA
SO Carbohydrate Research (1994), 251, 285-301
CODEN: CRBRAT; ISSN: 0008-6215
DT Journal
LA English
OS CASREACT 121:109622

=> d l10 1-16 ti
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L10 ANSWER 1 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Gene expression profiling in the prostate in the diagnosis and Gleason staging of high- and low-grade tumors

L10 ANSWER 2 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Soluble derivatives of human neutral hyaluronidase and preparation with transgenic cells for use in therapeutic modulation of glycosaminoglycan metabolism

L10 ANSWER 3 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN
TI The curcuminoids- and anthocyanins-responsive genes in human adipocytes and their use in screenings of anti-obesity and anti-diabetes drugs

L10 ANSWER 4 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Differentially expressed gene profile for diagnosing and treating mental disorders

L10 ANSWER 5 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Gene expression profiles for diagnosing breast cancer and identification of gene targets for therapy

L10 ANSWER 6 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Analysis of genetic information contained in peripheral blood for diagnosis, prognosis and monitoring treatment of allergy, infection and genetic disease in human

L10 ANSWER 7 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug containing the same

L10 ANSWER 8 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Soluble derivatives of human neutral hyaluronidase and their secretory manufacture for use in therapeutic modulation of glycosaminoglycan metabolism

L10 ANSWER 9 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Human tissue-specific housekeeping genes identified by expression profiling

L10 ANSWER 10 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Methods for diagnosing interstitial lung diseases using biomarkers

identified by microarray gene expression profiling

L10 ANSWER 11 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Novel pharmaceutical composition of interferon gamma or pirfenidone combined with molecular diagnostics for the improved treatment of interstitial lung diseases

L10 ANSWER 12 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Endocrine disruptor screening using DNA chips of endocrine disruptor-responsive genes

L10 ANSWER 13 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Gene markers useful for detecting skin damage in response to ultraviolet radiation

L10 ANSWER 14 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Screening methods to identify compounds that modulate a gene expression response of a cell to ultraviolet radiation exposure

L10 ANSWER 15 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN
TI The glycan structure of albumin Redhill, a glycosylated variant of human serum albumin

L10 ANSWER 16 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Analysis of the chromosome sequence of the legume symbiont Sinorhizobium meliloti strain 1021

=> d l10 13 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L10 ANSWER 13 OF 16 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Gene markers useful for detecting skin damage in response to ultraviolet radiation
AB The cellular response to UV radiation exposure has been characterized on the mol. level through the use of high d. gene array technol. Nucleic acid mols. and protein mols., the expression of which are repressed or induced in response to UV radiation exposure, are identified according to a temporal pattern of altered expression post UV radiation exposure. Methods are disclosed that utilized these UV radiation-regulated mols. as markers for UV radiation exposure. Other screening methods of the invention are designed for the identification of compds. that modulate the response of a cell to UV radiation exposure. The invention also provides compns. useful for drug screening or pharmaceuticals purposes.
AN 2002:185378 HCAPLUS <<LOGINID::20071214>>
DN 136:212896
TI Gene markers useful for detecting skin damage in response to ultraviolet radiation
IN Blumenberg, Miroslav
PA New York University School of Medicine, USA
SO PCT Int. Appl., 274 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002020849	A2	20020314	WO 2001-US28214	20010907 <--
	WO 2002020849	A3	20030703		

W: AU, CA, JP, SG
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

```
     US 2003073888         A1    20030417    US 2001-948020          20010906 <--
     US 7105292            B2    20060912
     CA 2423247            A1    20020314    CA 2001-2423247         20010907 <--
     AU 2001090699         A5    20020322    AU 2001-90699           20010907 <--
     EP 1390528            A2    20040225    EP 2001-970721          20010907 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI, CY, TR
     JP 2004527218         T     20040909    JP 2002-525854          20010907 <--
PRAI US 2000-231061P       P     20000908  <--
     WO 2001-US28214       W     20010907  <--


=> d his

     (FILE 'HOME' ENTERED AT 16:08:17 ON 14 DEC 2007)

     FILE 'HCAPLUS' ENTERED AT 16:11:32 ON 14 DEC 2007
L1         47700 S SIAL? OR DISIAL?
L2         62755 S ASPARAGINE OR ASP
L3        348157 S (FATTY ACID) OR HEXANOIC OR HEPTANOIC OR OCTANOIC OR NONANOIC
L4         25132 S INFLUENZA
L5          1016 S L1 AND L2
L6            29 S L1 AND L2 AND L3
L7            36 S L1 AND L2 AND L4
L8             7 S L1 AND L2 AND L3 AND L4
L9           907 S L5 AND (PY<2004 OR AY<2004 OR PRY<2004)
L10           16 S L6 AND (PY<2004 OR AY<2004 OR PRY<2004)
L11           27 S L7 AND (PY<2004 OR AY<2004 OR PRY<2004)
L12            5 S L8 AND (PY<2004 OR AY<2004 OR PRY<2004)

     FILE 'STNGUIDE' ENTERED AT 16:11:55 ON 14 DEC 2007

     FILE 'HCAPLUS' ENTERED AT 16:12:23 ON 14 DEC 2007

     FILE 'STNGUIDE' ENTERED AT 16:12:23 ON 14 DEC 2007

     FILE 'HCAPLUS' ENTERED AT 16:16:17 ON 14 DEC 2007

     FILE 'STNGUIDE' ENTERED AT 16:16:18 ON 14 DEC 2007

     FILE 'HCAPLUS' ENTERED AT 16:17:57 ON 14 DEC 2007

     FILE 'STNGUIDE' ENTERED AT 16:17:57 ON 14 DEC 2007

     FILE 'HCAPLUS' ENTERED AT 16:18:20 ON 14 DEC 2007

     FILE 'STNGUIDE' ENTERED AT 16:18:21 ON 14 DEC 2007

     FILE 'HCAPLUS' ENTERED AT 16:19:21 ON 14 DEC 2007

     FILE 'STNGUIDE' ENTERED AT 16:19:21 ON 14 DEC 2007

=> log hold
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               0.06      63.15

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                               0.00      -8.58

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:19:27 ON 14 DEC 2007
```

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'STNGUIDE' AT 16:41:28 ON 14 DEC 2007
FILE 'STNGUIDE' ENTERED AT 16:41:28 ON 14 DEC 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	63.15

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-8.58

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.12	63.21

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-8.58

FILE 'REGISTRY' ENTERED AT 16:42:38 ON 14 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 DEC 2007 HIGHEST RN 957969-84-5
DICTIONARY FILE UPDATES: 13 DEC 2007 HIGHEST RN 957969-84-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10562059asparfatty.str





chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 20 21 22 23 26
ring nodes :
14 15 16 17 18 19
chain bonds :
1-2 1-6 1-13 2-3 2-8 3-4 3-11 3-12 4-5 4-7 7-9 7-14 8-10 8-20 20-21
20-22 22-23 23-26
ring bonds :
14-15 14-19 15-16 16-17 17-18 18-19
exact/norm bonds :
1-6 1-13 2-8 4-5 4-7 7-14 8-20 14-15 14-19 15-16 16-17 17-18 18-19
20-21

exact bonds :
1-2 2-3 3-4 3-11 3-12 7-9 8-10 20-22 22-23 23-26

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom
19:Atom 20:CLASS
21:CLASS 22:CLASS 23:CLASS 26:CLASS

L13 STRUCTURE UPLOADED

=> d l13
L13 HAS NO ANSWERS
L13 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l13
SAMPLE SEARCH INITIATED 16:43:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       49 TO ITERATE

100.0% PROCESSED       49 ITERATIONS                                  2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          560 TO     1400
PROJECTED ANSWERS:               2 TO      124

L14           2 SEA SSS SAM L13

=> d l14 scan

L14  2 ANSWERS   REGISTRY  COPYRIGHT 2007 ACS on STN
IN   L-Asparagine, N-[2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-N2-(1-
     oxododecyl)-
MF   C24 H43 N3 O9

Absolute stereochemistry.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L14 2 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN L-Asparagine, N-[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→3)-O-[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-N2-(1-oxodecyl)- (9CI)
MF C98 H162 N8 O65

Absolute stereochemistry.



PAGE 1-B



PAGE 2-A



PAGE 2-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l13 sss full
FULL SEARCH INITIATED 16:43:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 896 TO ITERATE

100.0% PROCESSED 896 ITERATIONS 38 ANSWERS
SEARCH TIME: 00.00.01

L15 38 SEA SSS FUL L13

=>
Uploading C:\Program Files\Stnexp\Queries\10562059sialyl.str



chain nodes :
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
ring nodes :
1 2 3 4 5 6
chain bonds :
1-15 1-24 2-13 2-23 3-7 3-18 5-16 5-17 6-25 6-26 7-8 7-10 7-19 8-9
8-11 8-20 9-12 9-21 9-22 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 1-15 2-3 2-13 3-4 4-5 5-6 5-16 7-10 8-11 9-12 13-14
exact bonds :
1-24 2-23 3-7 3-18 5-17 6-25 6-26 7-8 7-19 8-9 8-20 9-21 9-22

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS

L16 STRUCTURE UPLOADED

=> d l16
L16 HAS NO ANSWERS
L16 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l16
SAMPLE SEARCH INITIATED 16:44:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       715 TO ITERATE

100.0% PROCESSED      715 ITERATIONS                                  50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        12696 TO    15904
PROJECTED ANSWERS:            5841 TO     8079

L17          50 SEA SSS SAM L16

=> s l16 sub=l15
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full
FULL SUBSET SEARCH INITIATED 16:44:20 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -        5 TO ITERATE

100.0% PROCESSED        5 ITERATIONS                                   5 ANSWERS
SEARCH TIME: 00.00.01

L18           5 SEA SUB=L15 SSS FUL L16

=> d l18 scan

L18  5 ANSWERS   REGISTRY  COPYRIGHT 2007 ACS on STN
IN   L-Asparagine, N-[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-
     galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-
     glucopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→3)-O-[O-
     (N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-
     (1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-
     (1→2)-α-D-mannopyranosyl-(1→6)]-O-β-D-
     mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-
     glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-
     glucopyranosyl]-N2-(1-oxodecyl)- (9CI)
MF   C98 H162 N8 O65

Absolute stereochemistry.
```

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L18 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN L-Asparagine, N-[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→3)-O-[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-N2-(1-oxodocosyl)- (9CI)
MF C110 H186 N8 O65

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L18 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN L-Asparagine, N-[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→3)-O-[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-N2-(1-oxotetradecyl)- (9CI)
MF C102 H170 N8 O65

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L18 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN L-Asparagine, N-[O-(N-acetyl-α-neuraminosyl)-[2→3(or 2→6)]-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→3)-O-[O-(N-acetyl-α-neuraminosyl)-[2→3(or 2→6)]-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-N2-(1-oxohexadecyl)- (9CI)
MF C104 H174 N8 O65
CI IDS

CM 1

PAGE 1-A



PAGE 1-B



PAGE 2-A



CM 2

Absolute stereochemistry.



L18 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN L-Asparagine, N-[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→3)-O-[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-N2-(1-oxooctadecyl)- (9CI)
MF C106 H178 N8 O65

Absolute stereochemistry.



PAGE 1-B



PAGE 2-A



PAGE 2-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

```
=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                       213.65     276.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                         0.00      -8.58

FILE 'CAPLUS' ENTERED AT 16:44:36 ON 14 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 14 Dec 2007  VOL 147 ISS 26
FILE LAST UPDATED: 13 Dec 2007  (20071213/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l18
L19           2 L18

=> d l19 1-2 ti abs bib

L19  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug
     containing the same
AB   Disclosed are a disialoundecasaccharide chain asparagine/fatty acid amide,
     a medical drug containing the same, and a medical drug containing
     disialoundecasaccharide chain asparagine.  A disialoundecasaccharide chain
     asparagine-decanoic acid amide was prepared from actinase-E-treated
     sialylglycopeptide (SGP) and decanoic acid.  The obtained compound showed
     anti-influenzavirus activity in vitro.
AN   2005:14446  CAPLUS <<LOGINID::20071214>>
DN   142:120505
TI   Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug
     containing the same
IN   Kajihara, Yasuhiro; Maeda, Hiroaki; Fukae, Kazuhiro
PA   Otsuka Chemical Co., Ltd., Japan; Sanyo Chemical Industries, Ltd.
SO   PCT Int. Appl., 27 pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
PI   WO 2005000906         A1    20050106    WO 2004-JP9521          20040629
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
```

```
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
            LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
            NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
            TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
            EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
            SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
            SN, TD, TG
    AU 2004252028        A1    20050106    AU 2004-252028         20040629
    CA 2529162           A1    20050106    CA 2004-2529162        20040629
    EP 1640383           A1    20060329    EP 2004-746990         20040629
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
           IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
    CN 1809594           A     20060726    CN 2004-80017447       20040629
    US 2007105813        A1    20070510    US 2005-562059         20051222
PRAI JP 2003-187931      A     20030630
    WO 2004-JP9521       W     20040629
RE.CNT  5     THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19  ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Model glycoconjugates consisting of biantennary N-glycans coupled to fatty
     acids:  synthesis and diffraction study
AB   Isolated glycopeptides of the N-acetyllactosaminic type, typically present
     on cell surface membranes, were linked through their NH2-terminus to
     activated palmitic acid.  The method used was quant. for neg.-charged
     glycans and for neutral glycans.  The liposaccharides thus obtained adopt,
     in concentrated water solns., mesomorphic structures which were studied by
x-ray
     diffraction anal.  The comportment of charged and uncharged
     liposaccharides was compared.
AN   1986:48242  CAPLUS <<LOGINID::20071214>>
DN   104:48242
TI   Model glycoconjugates consisting of biantennary N-glycans coupled to fatty
     acids:  synthesis and diffraction study
AU   Michel, Veronique; Gallot, Bernard
CS   Cent. Biophys. Mol., CNRS, Orleans, 45071, Fr.
SO   Makromolekulare Chemie (1985), 186(11), 2365-74
     CODEN: MACEAK; ISSN: 0025-116X
DT   Journal
LA   English


=> d his

     (FILE 'HOME' ENTERED AT 16:08:17 ON 14 DEC 2007)

     FILE 'HCAPLUS' ENTERED AT 16:11:32 ON 14 DEC 2007
L1        47700 S SIAL? OR DISIAL?
L2        62755 S ASPARAGINE OR ASP
L3       348157 S (FATTY ACID) OR HEXANOIC OR HEPTANOIC OR OCTANOIC OR NONANOIC
L4        25132 S INFLUENZA
L5         1016 S L1 AND L2
L6           29 S L1 AND L2 AND L3
L7           36 S L1 AND L2 AND L4
L8            7 S L1 AND L2 AND L3 AND L4
L9          907 S L5 AND (PY<2004 OR AY<2004 OR PRY<2004)
L10          16 S L6 AND (PY<2004 OR AY<2004 OR PRY<2004)
L11          27 S L7 AND (PY<2004 OR AY<2004 OR PRY<2004)
L12           5 S L8 AND (PY<2004 OR AY<2004 OR PRY<2004)

     FILE 'STNGUIDE' ENTERED AT 16:11:55 ON 14 DEC 2007
```

```
     FILE 'HCAPLUS' ENTERED AT 16:12:23 ON 14 DEC 2007

     FILE 'STNGUIDE' ENTERED AT 16:12:23 ON 14 DEC 2007

     FILE 'HCAPLUS' ENTERED AT 16:16:17 ON 14 DEC 2007

     FILE 'STNGUIDE' ENTERED AT 16:16:18 ON 14 DEC 2007

     FILE 'HCAPLUS' ENTERED AT 16:17:57 ON 14 DEC 2007

     FILE 'STNGUIDE' ENTERED AT 16:17:57 ON 14 DEC 2007

     FILE 'HCAPLUS' ENTERED AT 16:18:20 ON 14 DEC 2007

     FILE 'STNGUIDE' ENTERED AT 16:18:21 ON 14 DEC 2007

     FILE 'HCAPLUS' ENTERED AT 16:19:21 ON 14 DEC 2007

     FILE 'STNGUIDE' ENTERED AT 16:19:21 ON 14 DEC 2007

     FILE 'REGISTRY' ENTERED AT 16:42:38 ON 14 DEC 2007
L13             STRUCTURE UPLOADED
L14           2 S L13
L15          38 S L13 SSS FULL
L16             STRUCTURE UPLOADED
L17          50 S L16
L18           5 S L16  SUB=L15 FULL

     FILE 'CAPLUS' ENTERED AT 16:44:36 ON 14 DEC 2007
L19           2 S L18

=> log hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       6.13     282.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -1.56     -10.14

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:44:51 ON 14 DEC 2007

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 16:56:19 ON 14 DEC 2007
FILE 'CAPLUS' ENTERED AT 16:56:19 ON 14 DEC 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       6.13     282.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
```

```
                                                    ENTRY     SESSION
CA SUBSCRIBER PRICE                                  -1.56      -10.14

=> d l19 1-2 ti abs bib

L19  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug
     containing the same
AB   Disclosed are a disialoundecasaccharide chain asparagine/fatty acid amide,
     a medical drug containing the same, and a medical drug containing
     disialoundecasaccharide chain asparagine.  A disialoundecasaccharide chain
     asparagine-decanoic acid amide was prepared from actinase-E-treated
     sialylglycopeptide (SGP) and decanoic acid.  The obtained compound showed
     anti-influenzavirus activity in vitro.
AN   2005:14446  CAPLUS <<LOGINID::20071214>>
DN   142:120505
TI   Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug
     containing the same
IN   Kajihara, Yasuhiro; Maeda, Hiroaki; Fukae, Kazuhiro
PA   Otsuka Chemical Co., Ltd., Japan; Sanyo Chemical Industries, Ltd.
SO   PCT Int. Appl., 27 pp.
     CODEN: PIXXD2
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ---------------     ----   --------    --------------------     --------
PI   WO 2005000906        A1    20050106    WO 2004-JP9521           20040629
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     AU 2004252028        A1    20050106    AU 2004-252028           20040629
     CA 2529162           A1    20050106    CA 2004-2529162          20040629
     EP 1640383           A1    20060329    EP 2004-746990           20040629
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
     CN 1809594           A     20060726    CN 2004-80017447         20040629
     US 2007105813        A1    20070510    US 2005-562059           20051222
PRAI JP 2003-187931       A     20030630
     WO 2004-JP9521       W     20040629
RE.CNT  5     THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19  ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Model glycoconjugates consisting of biantennary N-glycans coupled to fatty
     acids:  synthesis and diffraction study
AB   Isolated glycopeptides of the N-acetyllactosaminic type, typically present
     on cell surface membranes, were linked through their NH2-terminus to
     activated palmitic acid.  The method used was quant. for neg.-charged
     glycans and for neutral glycans.  The liposaccharides thus obtained adopt,
     in concentrated water solns., mesomorphic structures which were studied by
x-ray
     diffraction anal.  The comportment of charged and uncharged
     liposaccharides was compared.
AN   1986:48242  CAPLUS <<LOGINID::20071214>>
DN   104:48242
```

TI Model glycoconjugates consisting of biantennary N-glycans coupled to fatty acids: synthesis and diffraction study
AU Michel, Veronique; Gallot, Bernard
CS Cent. Biophys. Mol., CNRS, Orleans, 45071, Fr.
SO Makromolekulare Chemie (1985), 186(11), 2365-74
CODEN: MACEAK; ISSN: 0025-116X
DT Journal
LA English

=> y
Y IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d l19 1-2 ti hitstr

L19 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
TI Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug containing the same
IT 821005-44-1P 821005-45-2P 821005-46-3P
821005-47-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(disialoundecasaccharide chain asparagine-fatty acid amides suitable for use as anti-influenzavirus agents)
RN 821005-44-1 CAPLUS
CN L-Asparagine, N-[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→3)-O-[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-N2-(1-oxodecyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



RN 821005-45-2 CAPLUS

CN L-Asparagine, N-[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→3)-O-[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-N2-(1-oxotetradecyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



RN 821005-46-3 CAPLUS

CN L-Asparagine, N-[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→3)-O-[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-N2-(1-oxooctadecyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



RN 821005-47-4 CAPLUS

CN L-Asparagine, N-[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→3)-O-[O-(N-acetyl-α-neuraminosyl)-(2→6)-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-N2-(1-oxodocosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



L19 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

TI Model glycoconjugates consisting of biantennary N-glycans coupled to fatty acids: synthesis and diffraction study

IT 99697-46-8P
RL: PRP (Properties); PREP (Preparation)
(preparation and structure of, as model glycoconjugate)

RN 99697-46-8 CAPLUS

CN L-Asparagine, N-[O-(N-acetyl-α-neuraminosyl)-[2→3(or 2→6)]-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-O-α-D-mannopyranosyl-(1→3)-O-[O-(N-acetyl-α-neuraminosyl)-[2→3(or 2→6)]-O-β-D-galactopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)]-O-β-D-mannopyranosyl-(1→4)-O-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-N2-(1-oxohexadecyl)- (9CI) (CA INDEX NAME)

CM 1

CRN 99697-45-7
CMF C82 H140 N6 O49

PAGE 1-A



PAGE 1-B



PAGE 2-A



CM 2

CRN 21646-00-4
CMF C11 H19 N O9

Absolute stereochemistry.



=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	17.82	294.68

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.12	-11.70

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:56:44 ON 14 DEC 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 18:05:24 ON 14 DEC 2007
FILE 'CAPLUS' ENTERED AT 18:05:24 ON 14 DEC 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)s

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	17.82	294.68

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.12	-11.70

=> s l15/thu
12 L15
961352 THU/RL
L20 2 L15/THU
(L15 (L) THU/RL)

=> d l20 1-2 ti

L20 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
TI Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug containing the same

L20 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
TI Comparison of the biological activity of synthetic N-acylated asparagine or serine linked monosaccharide lipid A analogs

=> d l20 2 ti abs bib

L20 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
TI Comparison of the biological activity of synthetic N-acylated asparagine or serine linked monosaccharide lipid A analogs
AB The mitogenicity, lethal toxicity, induction of tumor necrosis factor (TNF), production of nitric oxide (NO) and antitumor activity against Meth A fibrosarcoma by chemical synthesized N-acylated asparagine-linked (A-701, A-702 and A-703) or N-acylated serine-linked (A-607) nonphosphorylated acylglucosamine and 4-O-phosphorylated acylglucosamine (A-103) derived lipid A analogs were determined Compound A-607 (with tetradecanoyl and (R)-3-tetradecanoyloxytetradecanoyl at the C-2 and C-3 positions) induced a significant incorporation of 3H-thymidine into splenocytes of C3H/He mice at concns. ranging from 3.13 to 50 μM, but the mitogenic activity of A-701 (2-N-acetylglucosamine), A-702 (tetradecanoyl at the C-2), and A-703 (with (R)-tetradecanoyloxytetradecanoyl and tetradecanoyl at the C-2 and C-3) was very weak. The lethality of A-703 and A-103 (with (R)-3-tetradecanoyloxytetradecanoyl at the C-2 and C-3) was weaker than that of A-607 at doses of 300 and 750 nmol/kg in C57BL/6 mice loaded with D-galactosamine. Peritoneal macrophages, stimulated with A-701-A-703, caused production of TNF which induce L929 cell lysis in vitro, and A-703 showed a high production of TNF. The compds., except for A-607, exhibited little NO production by macrophages, but did induce the NO production in the presence of interferon gamma. Induction of TNF and NO inducible activity by A-703 was lower than that of A-607. A-703, A-607 and A-103 showed antitumor activity against Meth A fibrosarcoma in BALB/c mice. When A-703 or A-103 with muramyl dipeptide was administered, A-703 failed to show combined effects, but A-103 did. We concluded from these findings that the biol. potency of asparagine compds. appears to be placed between serine- and amino-free compds.
AN 1997:177307 CAPLUS <<LOGINID::20071214>>
DN 126:233106
TI Comparison of the biological activity of synthetic N-acylated asparagine or serine linked monosaccharide lipid A analogs
AU Shimizu, Tadayori; Iwamoto, Yoshihisa; Yanagihara, Yasutake; Ryoyama, Kazuo; Suhara, Yoshitomo; Ikeda, Kiyoshi; Achiwa, Kazuo
CS Department of Microbiology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan
SO Immunobiology (Stuttgart) (1996), 196(4), 321-331
CODEN: IMMND4; ISSN: 0171-2985
PB Fischer
DT Journal
LA English